P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA

Схожие документы

• Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells
  по: Inbal Sdayoor, и др.
  Опубликовано: (2025-04-01)
• P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE
  по: Mika Geva, и др.
  Опубликовано: (2023-08-01)
• Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
  по: Yaara Yerushalmi, и др.
  Опубликовано: (2022-12-01)
• P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
  по: Hila Magen, и др.
  Опубликовано: (2023-08-01)
• Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <i>de novo</i> large B-cell lymphoma and transformed low-grade B-cell lymphoma
  по: Ohad Benjamini, и др.
  Опубликовано: (2024-06-01)